CCM
CORT icon

Coldstream Capital Management’s Corcept Therapeutics CORT Stock Holding History

Coldstream Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$250K Buy
+2,877
New +$174K ﹤0.01% 1053
2025
Q4 		– Sell
-2,910
Closed -$242K – 1177
2025
Q3 		$242K Buy
+2,910
New +$211K ﹤0.01% 1042
2025
Q2 		– Sell
-2,350
Closed -$268K – 1599
2025
Q1 		$268K Buy
+2,350
New +$143K 0.01% 864

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Coldstream Capital Management's CORT Position: Q2 2026 in Review

Coldstream Capital Management opened a new position in Corcept Therapeutics (CORT) in Q2 2026: 2,877 shares worth $250K. The stake represents ﹤0.01% of the portfolio and ranks #1053 among its holdings. This is a return to the name: Coldstream Capital Management previously reported a position in CORT as recently as Q3 2025.

Coldstream Capital Management first reported a position in CORT in Q1 2025 and has held it in 3 quarters since. The position peaked at $268K in Q1 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Coldstream Capital Management held 2,877 shares of Corcept Therapeutics worth $250K as of Q2 2026.
  • Corcept Therapeutics was a new Coldstream Capital Management position in Q2 2026.
  • Corcept Therapeutics made up ﹤0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #1053 holding.
  • Coldstream Capital Management first reported a position in Corcept Therapeutics in Q1 2025 and has held it in 3 quarters since.
  • Coldstream Capital Management's Corcept Therapeutics position peaked at $268K in Q1 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.